MK-3120
MK-3120-002
Phase 2 small_molecule active
Quick answer
MK-3120 for Advanced/metastatic solid tumor disease is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Advanced/metastatic solid tumor disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active